Investor · 1 deal
Sydney, NSW
Every published round The George Institute for Global Health took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| GonGlobal | Pre-seed | Mar 2025 | $1.6m | Participant | Startup Daily, SmartCompany, Flying Fox Ventures portfolio |
Companies The George Institute for Global Health has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| GonGlobal | Mar 2025, Pre-seed | 1 | 0 |
Fund closes reported for The George Institute for Global Health, as distinct from the investments it has made.
Companies The George Institute for Global Health has backed that another company then bought. An exit for the holding, not a deal The George Institute for Global Health did.
| Name | Role | Sources |
|---|---|---|
| Professor Stephen MacMahon | Principal Director · Founder | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming The George Institute for Global Health. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UNSW Founders will run the NSW Government's new $4 million Diversity Pre-Accelerator Program for female and culturally diverse health founders, with the University of Newcastle also delivering support; applications open in July.
UNSW Founders partnered with Luminary Partners to invest $200,000 each in 18 early-stage deeptech startups across its 2025 accelerator cohorts, extending prior backing arrangements.
Weekly roundup detailing six Australian startup raises announced this week, covering Heidi Health, Instant, Esper, Trusst AI, Flowing Bee and GonGlobal, with investors, founders, valuations and earlier rounds.
Also Startup Daily
UNSW Founders honoured eight winners at its inaugural awards, with Forage taking Startup of the Year; the piece also notes Psylo's $5 million seed raise and this year's 10x Demo Day cohort.
Sydney dialysis startup Ellen Medical Devices received a $427,500 grant from AMGC's Commercialisation Fund to help manufacture its low-cost dialysis system, lifting total development investment to $1.04 million.
George Medicines, a George Institute spin-out developing combination blood pressure therapies, has appointed former CSL Behring chief medical officer Dr Charmaine Gittleson as an independent non-executive director as its drug GMRx2 enters Phase III trials.
Drug developer George Medicines has added Dr Charmaine Gittleson to its board as an independent non-executive director, bringing pharma and CSL Behring leadership experience as its hypertension candidate GMRx2 advances through Phase III trials.
George Medicines has begun two Phase III trials testing its triple-combination pill GMRx2 as a first-line hypertension treatment, with patient availability possible by 2023 pending US regulatory approval.
Drug developer George Medicines has started two Phase III trials of its GMRx2 triple-combination pill as a first-line hypertension therapy, enrolling patients across seven countries, with possible availability by 2023 pending US regulator approval.
Drug developer George Medicines has named Stefan König, previously a senior Takeda executive, as its chief executive, while chief business officer Karl Roberts moves into the chief operating officer role.
George Medicines has named Stefan König, previously a Takeda franchise head, as its new CEO, while Karl Roberts moves from Chief Business Officer to Chief Operating Officer. The company also announced US FDA clearance to begin Phase III trials of GMRx2.
Eleven startups from UNSW Founders' 2020 10x and Health 10x accelerators prepare for two online Demo Nights, each having received a $20,000 investment from UNSW.
The George Institute's commercial arm and its drug development company have secured $53 million from three Australian investors to speed commercialisation of medical research, with Brandon Capital's Ingmar Wahlqvist involved.